Natera Acquires Foresight Diagnostics

Natera Acquires Foresight Diagnostics

lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below

Cutting-edge IP adds

to Natera's portfolio of >500 issued or pending patents

Accelerates Natera's

expansion into lymphoma, where Foresight has developed a strong clinical position

Austin, TX, and Boulder, CO - December 5, 2025 -

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a

leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire

Foresight is a cancer diagnostics

company and CLIA-registered laboratory. The company's circulating tumor DNA (ctDNA)-based MRD tests leverage its patented

PhasED-Seq technology, targeting phased variants. With this technology, Foresight has reported performance with LOD95 of 0.3 parts

per million and detection below 0.1 ppm1.

Foresight was founded

by Stanford University physicians and scientists, Maximilian Diehn, M.D., Ph.D., Ash Alizadeh, M.D., Ph.D., and David Kurtz, M.D., Ph.D.,

together with Jake Chabon, Ph.D., Foresight's chief scientific officer and chief executive officer. The company has authored more

than 40 scientific publications and presentations and partnered with more than 30 biopharma and academic researchers.

The transaction combines Natera's

leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight's unique phased variant

technology and leadership in lymphoma. It builds on Natera's broad intellectual property portfolio for tumor-informed and

personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.

At the American Society of Hematology

(ASH) Annual Meeting beginning on December 6, Natera and Foresight will have a total of 15 abstracts featuring Signatera and

PhasED-Seq, including seven oral presentations.

Natera has closed the acquisition

of Foresight in an all-stock transaction consisting of a $275 million upfront with an additional $175 million in earnouts tied to the

achievement of revenue- and reimbursement-based milestones.

"This acquisition reinforces

Natera's position at the forefront of precision oncology," said Steve Chapman, chief executive officer of Natera. "Foresight's

phased variant technology and leadership in lymphoma complement Natera's strong capabilities in personalized MRD testing, improving

the value we can deliver to patients, clinicians, biopharma partners and the broader healthcare system."

"Foresight's mission has always been to improve the lives

of cancer patients worldwide through innovative diagnostics," said Chabon. "As we join Natera, I'm deeply grateful

to our employees, partners and investors who have helped bring us to this moment. Together, we can realize this mission on a far greater

scale, accelerating the pace of discovery across both hematologic and solid tumors."

Gibson, Dunn & Crutcher LLP is serving as legal counsel to

Natera. Wilson Sonsini Goodrich & Rosati is serving as legal counsel to Foresight, while Centerview Partners LLC is acting as

its financial advisor.

Natera is a global leader in cell-free DNA and precision medicine,

dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the

standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's

tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified

and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos,

California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained

in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations

will be achieved. These forward-looking statements, including those regarding the expected benefits of the Foresight acquisition, integration

of technologies, clinical and commercial opportunities, and future performance, represent Natera's expectations as of the date

of this press release, and are based on current expectations and are subject to risks and uncertainties that could cause actual results

to differ materially, including the ability to integrate Foresight's business, realize anticipated benefits, achieve expected clinical

or commercial outcomes, obtain or maintain reimbursement coverage, and respond to competitive or regulatory developments. Additional

risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K

and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,